Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
NCT06579105
Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: Research Site, Mobile, Alabama +120 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Heat, Microvascular Function and Aging
NCT06633198
Recruiting
Vascular dysfunction is a common factor in many chronic debilitating diseases, contributing to morbidity and mortality. With the onset of chronic disease or exposure to stress, the vasculature displays an inability to adequately respond to increased blood flow demands, manifesting in a reduced ability or altered mechanism of vasodilation. Aging is an independent risk factor in the development of cardiovascular disease, and reduces vasodilator capacity, or alters the mechanism by which vasodilati... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Aging
Register for Updates
Study of 68Ga-R10602
NCT06745804
Recruiting
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana +1 locations
Conditions: Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer
Register for Updates
Cardiovascular Risk Reduction for Adults With Food Insecurity Using Structured Incentives
NCT06818669
Recruiting
The overarching aim of this proposal is to test the efficacy and cost-effectiveness of CVD-FIT, a novel, multi-component intervention that includes three components: 1) monthly income supplementation; 2) weekly structured incentive for the purchase of healthy food options; and 3) evidence-based telephone delivered CVD risk reduction education and skills training in African Americans with food insecurity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: University at Buffalo, Buffalo, New York
Conditions: Cardiovascular Diseases
Register for Updates
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
NCT06881251
Recruiting
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: First OC Dermatology, Fountain Valley, California +22 locations
Conditions: Dermatitis, Atopic
Register for Updates
Remote Sputum Collection in Cystic Fibrosis
NCT06950892
Recruiting
Elexacaftor/Tezacaftor/Ivacaftor or Trikafta improves lung health in people with cystic fibrosis (CF), including decreased cough and mucous production. Diagnosing lung infections has become more challenging due to the decrease in sputum and rise of telehealth services. While the option of collecting sputum samples at home and sending them by mail may be feasible, uncertainty remains about how the collection of samples outside of clinic and delays in testing while in the mail impact infection det... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: National Jewish Health, Denver, Colorado +2 locations
Conditions: Cystic Fibrosis, Infections
Register for Updates
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
NCT02379429
Recruiting
Background: Urothelial cancer is cancer of the bladder, ureter, and urethra. Researchers want to better understand what changes in a person s cells and genes cause this cancer to form. This may help them find new ways to treat it. Objective: - To perform DNA sequencing to help researchers learn the differences between normal tissue and tumor tissue. Also, to learn how molecular changes - including gene changes - might help predict the course of disease and how people respond to therapy. Elig... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Bladder Cancer, Urinary Tract Cancer, Urothelial Cancer, Healthy Volunteers
Register for Updates
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738
Recruiting
This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia. This Registry will be open for enrollment for 7 years and all enrolled participants will be followed prospectively for a minimum of 2 years, and up to 9 years. Data will be collected from participating Registry Physicians, participants, and, where appropriate, parents/guardians who have provided informed co... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: Phoenix Childrens Hospital, Phoenix, Arizona +53 locations
Conditions: Pyruvate Kinase Deficiency
Register for Updates
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
NCT04188405
Recruiting
This phase II trial studies how well the combination of decitabine, venetoclax, and ponatinib work for the treatment of Philadelphia chromosome-positive acute myeloid leukemia or myeloid blast phase or accelerated phase chronic myelogenous leukemia. Drugs used in chemotherapy such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Register for Updates
C-Brace Prospective Registry
NCT04640584
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: Jonesboro P&O x Ottobock.care, Harrison, Arkansas +75 locations
Conditions: Pareses, Lower Extremity
Register for Updates
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Arizona Arthritis and Rheumatology Research PLLC, Avondale, Arizona +239 locations
Conditions: Arthritis, Psoriatic
Register for Updates
The CONFORM Pivotal Trial
NCT05147792
Recruiting
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Grandview Medical Center, Birmingham, Alabama +56 locations
Conditions: Atrial Fibrillation, Stroke
Register for Updates